Latest News for HKMPF
Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 price target, arguing the generic drugmaker's current valuation offers a compelling entry point. The 12-month target, based on a sum-of-the-parts valuation, implies a share price return of around 14%.
London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) chairman David Lenigas joined Proactive's Stephen Gunnion to discuss the Black Star gold project and the...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of...
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for HKMPF.
Senate Trading
No Senate trades found for HKMPF.
U.S. House Trading
No House trades found for HKMPF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.